Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
HLA-B	3106	ABACAVIR	CHEMBL1380		PharmGKB, FDA
HLA-B	3106	PHENYTOIN	CHEMBL16		FDA
HLA-B	3106	PAZOPANIB	CHEMBL477772		FDA
HLA-B	3106	OXCARBAZEPINE	CHEMBL1068		FDA
HLA-B	3106	CARBAMAZEPINE	CHEMBL108		PharmGKB, NCI, FDA	16981842
HLA-B	3106	THALIDOMIDE	CHEMBL468		NCI	7876469

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
HLA-B	HLA-B*58:01	*58:01	allopurinol	toxicity	yes	Association refers to T cell response. In vitro assays measured upregulation of CD107a on CD8 T cells in cultures of T cell lines (TCLs) generated from lymphocytes from allopurinol-naive individuals with a HLA-B*58:01 (n=7) positive or negative (n=7) genotype. Allopurinol or oxypurinol (an active metabolite of allopurinol)-specific TCLs were generated by incubating lymphocytes with different concentrations of drug (1, 10 or 100 ug/mL). Using 100ug/mL of drug, TCLs could be generated from 7/7 HLA-B*58:01+ donors, but only 1/7 HLA-B*58:01- donors. Authors state that this indicates high drug concentrations and the HLA-B*58:01 work synergistically to induce allopurinol/oxypurinol TCLs. Allopurinol-specific TCLs only recognized allopurinol, and oxypurinol-specific TCLs only recognized oxypurinol. One oxypurinol-sepcific TCL from a HLA-B*58:01 donor was able to recognize xanthine.	HLA-B *58:01 is associated with response to allopurinol.	24152157	1184759874
HLA-B	HLA-B*58:01	*58:01	allopurinol	toxicity	yes	required to induce a CD8+ T cell response compared to HLA-B*58:01 negative samples (EC50 was significantly lower in HLA-B*58:01+ cell cultures). In vitro assays measured upregulation of CD107a on CD8 T cells in cultures of T cell lines (TCLs) generated from lymphocytes from allopurinol-naive individuals with a HLA-B*58:01 (n=7) positive or negative (n=7) genotype. Allopurinol or oxypurinol (an active metabolite of allopurinol)-specific TCLs were generated by incubating lymphocytes with different concentrations of drug (1, 10 or 100 ug/mL).	HLA-B *58:01 is associated with decreased concentrations of allopurinol.	24152157	1184763829
HLA-B	HLA-B*15:01:01:01	*15:01:01:01	interferon beta-1a	efficacy	yes	Relapsing-remitting multiple sclerosis. The frequency of the *15 allele was more common in non-responders to interferon-beta-1a as compared to responders. Responders were defined as those with no sustained progression in the Expanded Disability Status Scale (EDSS) and no relapse during the follow-up period. Non-responders were defined as those with at least one relapse occurring during follow-up plus an increase of at least one point in the EDSS that continued for a minimum of two consecutive visits separated by a 6-month interval.	HLA-B *15:01:01:01 is associated with decreased response to interferon beta-1a in people with Multiple Sclerosis.	27020477	1448426926
HLA-B	HLA-B*44:02:01:01	*44:02:01:01	interferon alfa-2a, recombinant	efficacy	yes	Patients were described as being treated with interferon-alpha. The presence of an HLA-B*44 allele is associated with an increased likelihood of sustained response to ribavirin and interferon-alpha therapy. This annotation was completed on HLA-B*44:02:01:01 because this was the first *44 allele discovered. This result was NOT significant in those receiving interferon-alpha alone (n = 143).	HLA-B *44:02:01:01 is associated with increased response to interferon alfa-2a, recombinant and ribavirin in people with Hepatitis C.	12873589	1184349257
HLA-B	HLA-B*38:01:01	*38:01:01	peginterferon alfa-2a	efficacy	yes	Presence of the HLA-B*38 allele was associated with an increased likelihood of non-response to therapy. Non-response was defined as a failure to attain a negative hepatitis C viral RNA at week 24 from the start of treatment or a decline in hepatitis C viral RNA of >= 2 log10 IU/mL at week 12 of treatment.	HLA-B *38:01:01 is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C.	23360626	1184468132
HLA-B	HLA-B*40:01:01	*40:01:01	lamivudine	efficacy	yes	HLA-B*40:01 was a significant predictor of regimen modification due to treatment failure, with presence of the *40:01 allele leading to a decreased risk of regimen modification due to treatment failure.	HLA-B *40:01:01 is associated with response to lamivudine, nevirapine and stavudine in people with HIV.	25361850	1185012177
HLA-B	rs13437088	TT	etanercept	efficacy	yes		Genotype TT is associated with decreased response to etanercept in people with Psoriasis as compared to genotypes CC + CT.	28470127	1448631715